Genmab CEO: Three products may turn into five this year

Normally, it takes ten months for a marketing authorization to be processed in the US. Genmab hopes for an accelerated process, so the firm can get approval for two new products this year.

Photo: Tuala Hjarnø / Genmab / PR

BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Published: 25.02.21 at 11:41

Genmab's three winning horses may very well turn into five in the course of 2021.

"The most important milestone this year is that we hope to get two new products approved, which are basically created with Genmab techology. One is Johnson & Johnson's Amivantamab, and the other is Tisotumab Vedotin," Genmab CEO Jan van de Winkel tells Ritzau Finans.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

More from MedWatch

Hearing firms urge FDA to increase OTC safety requirements

Foto: Projekt Bear

A number of the world’s biggest hearing aid manufacturers have come together to encourage the US health authority to tighten the safety requirements for OTC hearing aids, which will hit the shelves in the US sometime this year.

Novo Nordisk launches oral semaglutide in India

Foto: Novo Nordisk / PR

Novo Nordisk’s diabetes drug, semaglutide, will be sold in the country in a similar price range as its injectable version.

Coloplast initiates trial of ostomy leakage product

Foto: Coloplast / PR

The medtech company will being clinically testing its ostomy add-on product, Heylo, in January.

Top news from MedWatch this week

Miss anything?

Danish bank cuts Genmab price target, retains "buy" recommendation

Foto: Stine Tidsvilde

Jyske Bank has adjusted its valuation of Genmab’s share price target to DKK 2850 (USD 434.4). Investors should continue to buy, the Danish bank says.

Further reading

Related articles